 

The transcript discusses the financial performance of West Pharmaceutical Services, a company that provides products and solutions for the containment and delivery of injectable medicines. Despite the challenges posed by COVID-19, West has remained focused on creating and delivering value to its stakeholders, with two priorities: the well-being and safety of its team members and the continuity of manufacturing and supply of components and solutions to its customers. West has experienced strong growth in the first quarter, with 13% organic sales growth and double-digit growth in adjusted earnings per share. The company's gross profit margin has also improved, driven by growth in high-value products. West has a strong balance sheet, with a cash balance of $335.3 million at March 31, 2020. The company's full-year 2020 net sales guidance is in a range of between $1.95 billion and $1.97 billion, with an estimated headwind of $26 million based on current foreign exchange rates. West is committed to supporting its customers in the development of potential solutions to address COVID-19, and the company is optimistic about its long-term growth strategy.